CD4 and type 1 diabetes mellitus: However, in a recent Phase 2 clinical trial in children and adolescents with recent-onset T1D, a single dose of CD4+CD25hiCD127lo/− autologous expanded polyclonal Tregs did not prevent decline in β-cell function, despite the suppressive capacity of the expanded Tregs in vitro [122].